mTOR Pathway

The mTOR pathway plays a major role in multiple critical cellular processes. Aberrant mTOR pathway activation is associated with a broad range of diseases and frequently driven by alterations in MTOR.

nab Technology Platform

Aadi Bioscience’s lead investigational drug candidate product nab-sirolimus leverages albumin-bound nanoparticle technology.

nab-Sirolimus is based on a technology similar to ABRAXANE^® (nab-paclitaxel; Abraxis Bioscience acquired by Celgene Corp in 2010)

Albumin accumulates in tumor tissues, either due to the leaky capillary system and defective lymphatic drainage of tumors or through an active gp60/caveolae-mediated transport process across tumor blood vessel endothelium. Importantly, albumin is taken up by proliferating tumor cells via endocytosis and macropinocytosis, then catabolized by lysosomal degradation to support de novo protein synthesis, energy, and tumor growth. The accumulation of albumin in solid tumors provides potential rationale for albumin-based drug delivery systems to preferentially target tumors.

---

Preclinical Differentiation vs. Existing mTOR Inhibitors

In preclinical animal models, the nab technology investigational drug candidate nab-sirolimus has demonstrated advantages over existing mTOR inhibitors including:

To Learn More Please Visit our Publications Page.